James Burns
Chief Executive Officer at Locanabio, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey Ostrove | M | - |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 5 years |
Thomas Daniel | M | 70 |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 7 years |
Kush Parmar | M | 42 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Min Wang | M | - |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Eugene Yeo | M | 47 |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 8 years |
Jean George | F | 66 |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | - |
Cayce Denton | F | - |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | - |
Mark Chin | M | 42 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Paula Soteropoulos | F | 56 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | 4 years |
Albert Seymour | M | 56 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Rajul Jain | M | - |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | - |
Rajul Jain | M | - |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 4 years |
Adam Fowler | M | - |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 4 years |
Kouki Harasaki | M | - |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Nihal Sinha | M | - |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Nelles | M | - |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 4 years |
Katherine Bishop | M | 58 |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 1 years |
Edward Conner | M | 51 |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 18 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Burns
- Personal Network